Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nkarta Inc NKTX

Healthcare Biotechnology
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product... see more

Recent & Breaking News (NDAQ:NKTX)

Nkarta Announces June 2021 Investor Conference Schedule

GlobeNewswire May 25, 2021

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

GlobeNewswire May 13, 2021

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

GlobeNewswire May 6, 2021

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

GlobeNewswire April 28, 2021

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

GlobeNewswire March 25, 2021

Nkarta Announces February and March 2021 Investor Conference Schedule

GlobeNewswire February 17, 2021

Nkarta Reports Third Quarter 2020 Financial Results

GlobeNewswire November 12, 2020

Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101

GlobeNewswire November 12, 2020

Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire November 9, 2020

Nkarta Announces November & December 2020 Investor Conference Schedule

GlobeNewswire November 5, 2020

Nkarta Announces Leadership Changes

GlobeNewswire October 5, 2020

Nkarta Announces October 2020 Investor Conference Schedule

GlobeNewswire September 29, 2020

Nkarta Announces September 2020 Virtual Investor Conference Schedule

GlobeNewswire September 8, 2020

Nkarta Reports Second Quarter 2020 Financial Results

GlobeNewswire August 20, 2020

Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 14, 2020

Nkarta Announces Pricing of Initial Public Offering

GlobeNewswire July 10, 2020